Evofem Biosciences Stock Forecast, Price & News

Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions

Is Evofem Biosciences a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Evofem Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVFM, but not buy additional shares or sell existing shares.
View analyst ratings for Evofem Biosciences or view top-rated stocks.

How has Evofem Biosciences' stock been impacted by Coronavirus (COVID-19)?

Evofem Biosciences' stock was trading at $5.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EVFM stock has decreased by 91.5% and is now trading at $0.4390.
View which stocks have been most impacted by COVID-19.

When is Evofem Biosciences' next earnings date?

Evofem Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Evofem Biosciences.

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences, Inc. (NASDAQ:EVFM) issued its earnings results on Monday, November, 15th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.18. Evofem Biosciences had a negative net margin of 4,011.48% and a negative trailing twelve-month return on equity of 1,593.89%. During the same quarter in the previous year, the business earned ($0.33) EPS.
View Evofem Biosciences' earnings history.

What price target have analysts set for EVFM?

2 Wall Street analysts have issued 1 year price targets for Evofem Biosciences' stock. Their forecasts range from $1.00 to $2.00. On average, they expect Evofem Biosciences' share price to reach $1.50 in the next twelve months. This suggests a possible upside of 241.7% from the stock's current price.
View analysts' price targets for Evofem Biosciences or view top-rated stocks among Wall Street analysts.

Who are Evofem Biosciences' key executives?

Evofem Biosciences' management team includes the following people:

• Saundra L. Pelletier, President, Chief Executive Officer & Director (LinkedIn Profile)
• Richard M. Murawski, Senior Vice President-Operations
• Justin J. File, Chief Financial Officer (LinkedIn Profile)
• Brandi Howard, Head-Medical Affairs
• Kelly Culwell, Chief Medical Officer

Who are some of Evofem Biosciences' key competitors?

Some companies that are related to Evofem Biosciences include 9 Meters Biopharma (NMTR), Akouos (AKUS), Sernova (SEOVF), Checkpoint Therapeutics (CKPT), CymaBay Therapeutics (CBAY), Theratechnologies (THERF), Connect Biopharma (CNTB), Aquestive Therapeutics (AQST), UroGen Pharma (URGN), Pieris Pharmaceuticals (PIRS), XOMA (XOMA), Syros Pharmaceuticals (SYRS), Citius Pharmaceuticals (CTXR), TherapeuticsMD (TXMD) and GX Acquisition (GXGX).
View all of EVFM's competitors.

What other stocks do shareholders of Evofem Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evofem Biosciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), OrganiGram (OGI), Gran Tierra Energy (GTE), Novan (NOVN) and KushCo (KSHB).

What is Evofem Biosciences' stock symbol?

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

Who are Evofem Biosciences' major shareholders?

Evofem Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.49%), Geode Capital Management LLC (0.86%), Fuller & Thaler Asset Management Inc. (0.70%), Millennium Management LLC (0.42%), Morgan Stanley (0.13%) and Tocqueville Asset Management L.P. (0.10%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Anthony Stephen O'brien, Justin J File, Justin J File, Kelly Culwell, Kim P Kamdar, Lisa Dale Rarick, Ltd Invesco, Russell Barrans, Saundra L Pelletier, Saundra L Pelletier and William Walmsley Hall.
View institutional ownership trends for Evofem Biosciences.

Which major investors are selling Evofem Biosciences stock?

EVFM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Millennium Management LLC, GSA Capital Partners LLP, Citadel Advisors LLC, Commonwealth Equity Services LLC, Tocqueville Asset Management L.P., and Jane Street Group LLC.
View insider buying and selling activity for Evofem Biosciences or view top insider-selling stocks.

Which major investors are buying Evofem Biosciences stock?

EVFM stock was bought by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., BlackRock Inc., Geode Capital Management LLC, Goldman Sachs Group Inc., and UBS Group AG. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Anthony Stephen O'brien, Justin J File, Kim P Kamdar, Lisa Dale Rarick, Ltd Invesco, Russell Barrans, Saundra L Pelletier, and William Walmsley Hall.
View insider buying and selling activity for Evofem Biosciences or or view top insider-buying stocks.

How do I buy shares of Evofem Biosciences?

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evofem Biosciences' stock price today?

One share of EVFM stock can currently be purchased for approximately $0.44.

How much money does Evofem Biosciences make?

Evofem Biosciences has a market capitalization of $68.14 million and generates $450 thousand in revenue each year. The biotechnology company earns $-142.31 million in net income (profit) each year or ($1.81) on an earnings per share basis.

How many employees does Evofem Biosciences have?

Evofem Biosciences employs 147 workers across the globe.

What is Evofem Biosciences' official website?

The official website for Evofem Biosciences is www.evofem.com.

Where are Evofem Biosciences' headquarters?

Evofem Biosciences is headquartered at 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130.

How can I contact Evofem Biosciences?

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at (858) 550-1900, via email at [email protected], or via fax at 844-828-2010.